Wilmer Eye Institute

Oluwatosin U. Smith, MD, and Peter J. McDonnell, MD, discuss their experience at EyeCon 2023, highlighting the latest updates in retina, cataract and refractive surgery, and the growing epidemic of myopia worldwide.

Peter J. McDonnell, MD, and Neda Shamie, MD, consider the transformative landscape of cataract surgery, highlighting the impact of small-aperture IOL technology. The conversation delves into its potential benefits, influence on the market, and the evolving role of cataract surgeons in guiding patients through advanced options.

Peter J. McDonnell's, MD, Chief medical editor of Ophthalmology times, editorial from the October 2023 issue.

Peter J. McDonnell, MD, and Neda Shamie, MD, discuss the transformative impact of minimally invasive glaucoma surgery (MIGS) on glaucoma care and its integration with cataract surgery, sharing insights and practical tips for ophthalmologists.

In this podcast episode, Ophthalmology Times' co-chief medical editors Peter J. McDonnell, MD, and Neda Shamie, MD, delve into the clinical nuances of Demodex blepharitis. Through personal anecdotes, they stress its underrecognized gravity and discuss diagnostic cues like collarettes. The experts share their enthusiasm for improved treatments, echoing the transformative impact seen in dry eye care.

Esen Akpek, MD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss ocular surface disease and the lifestyle choices that could affect eye health. As well as what The Tear Film & Ocular Surface Society is doing to promote research on the topic.

This subtype of artificial intelligence technology may have long-range implications for clinical trials.

Jefferson Doyle, MBBCh, MD, PhD, MHS, of the Wilmer Eye Institute at Johns Hopkins University School of Medicine, addresses myopic concerns, such as public health measures including time outdoors, as well as pharmacological approaches including the current atropine data that has been completed and ongoing studies.

Ophthalmology Times®' EyeCon co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute, and glaucoma specialist Oluwatosin U. Smith MD, from Glaucoma Associates of Texas, discuss some of the highlights of EyeCon 2022.

This December, the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide attendees with an end-of-year opportunity to meet their continuing medical education requirements. This activity has been approved for 12.50 AMA PRA Category 1 Credits™.

There literally are not enough hours in a day to allow physicians to comply with all the recommendations emanating from the various constituencies involved in issuing guidelines.

An interactive agenda at the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will foster an open exchange of ideas with fellow attendees from across the United States.

The setting for this year's Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide the opportunity for clinical interaction between faculty and attendees along with the practicality of information.

Optimal performance has a limited window.

The destination of Marco Island, Florida not only serves as an excellent backdrop for this year's Ophthalmology Times® EyeCon 2022 but also provides a unique opportunity for family members to see their ophthalmic loved ones in a professional light.

Co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland, and Oluwatosin U. Smith, MD, of Glaucoma Associates of Texas in Dallas break down the top reasons to attend this year's Ophthalmology Times® EyeCon 2022 in a series of video segments.

Surveys have found that burnout among physicians who deliver “primary care” is so bad that 20% of them intend to stop practicing.

According to a study published in 2016, approximately 250,000 deaths occur in the United States each year due to medical errors.

While there is currently no cure for blindness, an artificial vision system has undergone its first successful implantation, bringing with it the potential to restore partial vision to people who have lost their sight.

A team of investigators are working on a simple test that may someday identify those who can stop therapy.

Ophthalmologists continue to rise to the challenge amid myriad hurdles.